ReviewCancer science2018
Implementation of "clinical sequencing" in cancer genome medicine in Japan.
Review in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.Cancer science · 2025Article
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan.Cancers · 2024Article
- Young Adult Secondary Cancer After Proton Beam Therapy: A Case Study.Advances in radiation oncology · 2024Article
- The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan.Cancer biology & medicine · 2023Review
- Mission of the National Cancer Center Hospital in Japan to promote clinical trials for precision medicine.Cancer biology & medicine · 2023Article
- Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective study.Thoracic cancer · 2022Article
- Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine.Journal of personalized medicine · 2022Review
- Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.Cancers · 2022Review
- Primary Intracranial Spindle Cell Sarcoma,Clinical medicine insights. Case reports · 2022Article
- JCGA: the Japanese version of the Cancer Genome Atlas and its contribution to the interpretation of gene alterations detected in clinical cancer genome sequencing.Human genome variation · 2021Article
- Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- Pan-cancer analysis of non-coding recurrent mutations and their possible involvement in cancer pathogenesis.NAR cancer · 2021Article
- Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2020Review
- Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.Cancer science · 2020Article
- High Frequency ofDiagnostics (Basel, Switzerland) · 2019Article
- Mutation of the PTCH1 gene predicts recurrence of breast cancer.Scientific reports · 2019Article
- Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.The oncologist · 2019Article
- Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.BMC cancer · 2019Article
- Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.Cancer science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In oncology, actionable mutations (alterations) in cancer-associated genes are critical in terms of the selection of therapeutic approaches. Next-generation sequencing of tumor sample DNA (ie, clinical sequencing) can guide clinical management by providing diagnostic or prognostic data, and facilitating the identification of potential treatment regimens, such as molecular-targeted and immune checkpoint blockade therapies. In the USA, a variety of tumor-profiling multiplex gene panels have been developed and implemented for this purpose. In Japan, several academic institutions have now carried out detailed investigations of the feasibility and value of clinical sequencing, and cancer societies have issued consensus clinical practice guidance for next-generation sequencing-based gene panel tests. These efforts will facilitate the implementation of cancer genome medicine in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.